ACADIA Pharmaceuticals Inc. (ACAD): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACAD POWR Grades
- Quality is the dimension where ACAD ranks best; there it ranks ahead of 94.55% of US stocks.
- ACAD's strongest trending metric is Quality; it's been moving up over the last 177 days.
- ACAD's current lowest rank is in the Sentiment metric (where it is better than 28.98% of US stocks).
ACAD Stock Summary
- For ACAD, its debt to operating expenses ratio is greater than that reported by just 13.4% of US equities we're observing.
- With a price/sales ratio of 6.28, ACADIA PHARMACEUTICALS INC has a higher such ratio than 81.07% of stocks in our set.
- ACAD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 21.24% of US stocks.
- Stocks that are quantitatively similar to ACAD, based on their financial statements, market capitalization, and price volatility, are OVID, SPRO, FKWL, VYNE, and GANX.
- Visit ACAD's SEC page to see the company's official filings. To visit the company's web site, go to www.acadia-pharm.com.
ACAD Valuation Summary
- In comparison to the median Healthcare stock, ACAD's price/sales ratio is 15.69% higher, now standing at 5.9.
- Over the past 227 months, ACAD's price/sales ratio has gone down 11.6.
Below are key valuation metrics over time for ACAD.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ACAD | 2023-01-30 | 5.9 | 7.0 | -13.8 | -13.4 |
ACAD | 2023-01-27 | 5.9 | 7.1 | -13.8 | -13.5 |
ACAD | 2023-01-26 | 5.9 | 7.1 | -13.9 | -13.5 |
ACAD | 2023-01-25 | 5.9 | 7.1 | -13.9 | -13.6 |
ACAD | 2023-01-24 | 6.0 | 7.2 | -14.2 | -13.8 |
ACAD | 2023-01-23 | 6.0 | 7.3 | -14.2 | -13.9 |
ACAD Growth Metrics
- Its 5 year net cashflow from operations growth rate is now at 43.32%.
- The 4 year revenue growth rate now stands at 1022.82%.
- The 2 year cash and equivalents growth rate now stands at 17.82%.

The table below shows ACAD's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 511.503 | -113.301 | -217.344 |
2022-06-30 | 512.401 | -129.638 | -204.618 |
2022-03-31 | 493.059 | -141.84 | -214.478 |
2021-12-31 | 484.145 | -125.66 | -167.87 |
2021-09-30 | 474.394 | -130.028 | -191.536 |
2021-06-30 | 463.359 | -135.757 | -261.739 |
ACAD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ACAD has a Quality Grade of C, ranking ahead of 66.5% of graded US stocks.
- ACAD's asset turnover comes in at 0.606 -- ranking 51st of 682 Pharmaceutical Products stocks.
- AKBA, PBYI, and DRRX are the stocks whose asset turnover ratios are most correlated with ACAD.
The table below shows ACAD's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.606 | 0.980 | -0.702 |
2021-03-31 | 0.593 | 0.979 | -0.724 |
2020-12-31 | 0.573 | 0.977 | -0.744 |
2020-09-30 | 0.543 | 0.974 | -0.652 |
2020-06-30 | 0.515 | 0.972 | -0.541 |
2020-03-31 | 0.531 | 0.969 | -0.585 |
ACAD Price Target
For more insight on analysts targets of ACAD, see our ACAD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $25.53 | Average Broker Recommendation | 1.83 (Hold) |
ACAD Stock Price Chart Interactive Chart >
ACAD Price/Volume Stats
Current price | $19.84 | 52-week high | $28.06 |
Prev. close | $19.85 | 52-week low | $12.24 |
Day low | $19.74 | Volume | 443,186 |
Day high | $19.97 | Avg. volume | 1,210,649 |
50-day MA | $16.84 | Dividend yield | N/A |
200-day MA | $16.50 | Market Cap | 3.21B |
ACADIA Pharmaceuticals Inc. (ACAD) Company Bio
Acadia Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. The firm aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia. The company was founded in 1993 by Mark Brann, PhD., a professor at the University of Vermont, under the name Receptor Technologies. By 1997, the company established its headquarters in San Diego, California and changed its name to Acadia Pharmaceuticals Inc and currently employs over 400 people. Since 2015, Stephen R. Davis serves as Acadia’s Chief Executive Officer and member of the board of directors. Competition for Acadia includes Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, and off-label branded and generic antipsychotics.
Latest ACAD News From Around the Web
Below are the latest news stories about ACADIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACAD as an investment opportunity.
Acadia Pharmaceuticals: What''s Ahead In 2023ACADIA Pharmaceuticals had one major disappointment in 2022 but has some potential new drug approvals on the horizon. Click here to read my analysis of ACAD. |
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and DevelopmentSAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. Williamson will lead research and development at Acadia and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, Chief Executive Officer of Acadia. Dr. Williamson will succeed Dr. Srdjan Stankovic, whose planned retirement was announced last year. “We |
Acadia Pharmaceuticals bulls will need to be patient for nowAcadia Pharmaceuticals (ACAD) bulls will need to be patient for now as the company''s charts simply aren''t showing sustained strength, writes technical analyst Bruce Kamich….ACAD |
Opening Bell Analysts Research Calls for Tuesday, January 3This report was sent to Briefing.com subscribers earlier today. Research calls posted earlier this morning are available here. Upgrades: > ACADIA Pharmaceuticals (ACAD) upgraded to Buy from Neutral at Guggenheim; tgt $22 > Allegion (ALLE) upgraded to Buy from Hold at Vertical Research; tgt $128 > Becton Dickinson (BDX) upgraded to Buy from Neutral at […] |
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID (pimavanserin) Compared to Those Treated with Other Atypical AntipsychoticsAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID (pimavanserin) compared to other atypical antipsychotics over 12 months and across various subgroups. NUPLAZID is the only medication approved by the U.S. |
ACAD Price Returns
1-mo | 14.68% |
3-mo | 32.62% |
6-mo | 26.05% |
1-year | -21.61% |
3-year | -52.39% |
5-year | -30.02% |
YTD | 24.62% |
2022 | -31.79% |
2021 | -56.34% |
2020 | 24.96% |
2019 | 164.56% |
2018 | -46.30% |
Continue Researching ACAD
Here are a few links from around the web to help you further your research on Acadia Pharmaceuticals Inc's stock as an investment opportunity:Acadia Pharmaceuticals Inc (ACAD) Stock Price | Nasdaq
Acadia Pharmaceuticals Inc (ACAD) Stock Quote, History and News - Yahoo Finance
Acadia Pharmaceuticals Inc (ACAD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...